Table 1.
Pharmacokinetic parameters of TTI-101 after oral administration
| Maximum Plasma Concentration, μg/mL | Statistical Significance | Time to Maximal Plasma Levels, h | Half-Time, h | |
|---|---|---|---|---|
| 10 mg/kg TTI-101 | ||||
| Sham | 3.21 ± 0.48 | 1 ± 0.3 | 25.98 ± 1.04 | |
| CKD | 3.02 ± 0.53 | 2.87 ± 0.79 | 32.08 ± 1.36 | |
| 30 mg/kg TTI-101 | ||||
| Sham | 9.23 ± 0.66 | P < 0.05 | 0.65 ± 0.14 | 9.42 ± 0.03 |
| CKD | 8.59 ± 1.03 | P < 0.05 | 0.91 ± 0.26 | 6.15 ± 0.03 |
| 100 mg/kg TTI-101 | ||||
| Sham | 11.05 ± 0.81 | P < 0.05 | 1 ± 0.2 | 8.2 ± 0.38 |
| CKD | 9.71 ± 0.56 | P < 0.05 | 0.9 ± 0.1 | 10.02 ± 2.4 |
Data are expressed as means ± SE. TTI-101 was single-dose gavage fed to rats. TTI-101 in plasma was measured, and pharmacokinetics were analyzed using the PKSolver program. For maximum plasma concentrations, statistical comparison with sham control rats at 10 mg/kg TTI-101 was done using a Student’s t test at a significance level of P < 0.05.